Wall Street equity research analysts covering Stereotaxis (STXS) maintain an average consensus 12-month price target resting around $3.00 to $3.33 per share. These projections are supported by institutional expectations for accelerating revenue growth from its core robotic navigation platforms and proprietary catheter product commercialization, representing significant percentage upside relative to its small-cap market trading range.